Pamiparib in combination with surufatinib in patients with platinum-resistant ovarian cancer who received prior poly (ADP-ribose) polymerase inhibitors: A multicenter, single-arm, phase Ib/II trial (post-PARPi trial)

Category Primary study
ConferenceSociety of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women's Cancer
Year 2025
This article has no abstract
Epistemonikos ID: 2ab7c2d6b81867794077b29a526a4f9dafa75c78
First added on: Oct 17, 2025